HER2 Antibody Composition with Acidic Variant Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HER2 antibodies, such as Trastuzumab, have limitations in effectively inhibiting HER dimerization and treating HER2-positive cancers, particularly in maintaining pharmacokinetic profiles and addressing variant forms like glycated, disulfide reduced, and non-reducible variants.
Innovation Solution
A composition comprising a main species HER2 antibody that binds to domain II of HER2, along with acidic variants like glycated, deamidated, disulfide reduced, and non-reducible variants, ensuring these variants constitute less than 25% of the total, and using specific methods like ion exchange chromatography and CE-SDS for evaluation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current HER2 antibodies like Trastuzumab are used, then HER2-positive cancers can be treated, but the inhibition of HER dimerization is limited and pharmacokinetic profiles are not maintained
Solution Approach 1:
The patent modifies the antibody structure by changing parameters such as amino acid sequences in the variable regions, glycosylation patterns, and post-translational modifications to enhance binding affinity and functional activity against HER2, thereby improving dimerization inhibition while maintaining pharmacokinetic profiles
Solution Approach 2:
The invention creates composite antibody molecules that combine multiple functional features including different isotypes, glycosylation states, and post-translational modifications to achieve synergistic effects that improve both therapeutic efficacy and dimerization inhibition
2Adaptability or versatility
If acidic variants like glycated, disulfide reduced, and non-reducible variants are present, then antibody composition is complex, but these variants constitute less than 25% of the total
Solution Approach 1:
The patent establishes specific parameters for variant control by defining acceptable ranges for acidic variants (less than 25%) and implementing process controls to manage glycosylation, disulfide bonding, and other post-translational modifications during antibody production
Solution Approach 2:
The invention incorporates analytical methods such as ion exchange chromatography and CE-SDS to monitor and detect acidic variants, providing feedback for process optimization and ensuring consistent product quality across batches
Data Source
AI summary
A composition comprising a main species HER2 antibody that binds to domain II of HER2 and acidic variants thereof is described. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.